Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization

RRx-001, an experimental systemically non-toxic epi-immunotherapeutic agent, which potentiates the resensitization of resistant cancer cells to formerly effective therapies, is under active investigation in several clinical trials that are based on sequential or concomitant rechallenge to resistant...

Full description

Bibliographic Details
Main Authors: Corey A. Carter, Bryan T. Oronsky, Scott Z. Caroen, Jan J. Scicinski, Pedro Cabrales, Tony Reid, Aiste Degesys, John Jenkins, Christina Brzezniak
Format: Article
Language:English
Published: Karger Publishers 2016-01-01
Series:Case Reports in Oncology
Subjects:
Non-small cell lung cancer
RRx-001
Partial response
Refractory EGFR
Platinum doublets
Online Access:http://www.karger.com/Article/FullText/443725

Internet

http://www.karger.com/Article/FullText/443725

Similar Items